What You Should Know:
– CancerIQ, a Chicago, IL-based precision health platform focused on empowering healthcare providers to personalize cancer prevention and early detection announced it has secured a growth funding package from Decathlon Capital Partners.
– While specific financial details of the transaction were not disclosed, the investment will enable CancerIQ to further develop its digital tools, introduce new offerings, and strengthen partnerships with healthcare providers nationwide.
Personalized Cancer Detection
CancerIQ aims to stay at the forefront of precision health technology. The company’s focus on continuous innovation ensures that healthcare providers have access to the most advanced tools for identifying cancer risks, guiding genetic testing, and improving patient adherence to personalized care plans.
CancerIQ’s platform is designed to seamlessly integrate into electronic health record (EHR) workflows, making it an invaluable tool for healthcare providers in various clinical settings. The platform equips providers with the ability to identify patients’ lifetime and hereditary cancer risks accurately. With this information, providers can offer personalized cancer prevention strategies and early detection plans tailored to each patient’s unique risk profile.
One of the key features of CancerIQ’s platform is its user-friendly interface, which makes it accessible to providers regardless of their technical expertise. The platform utilizes up-to-date clinical guidelines to ensure that genetic testing and personalized care plans are based on the latest medical evidence. This approach not only improves the uptake of genetic testing but also enhances patient outcomes by promoting adherence to personalized cancer care plans.
“The CancerIQ platform is designed to help providers ensure every patient receives the necessary care to manage their individual cancer risk — from prevention and early detection to treatment and survivorship,” Ayodele said. “It’s time to abandon the one-size-fits-all approach to cancer prevention and ensure people get the care they need to stay ahead of cancer,” said Feyi Olopade Ayodele, Co-Founder and Chief Executive Officer of CancerIQ.